Alcidion Group (ASX:ALC): FY26 Results, Healthcare Software Expansion and Contract Developments

Aditi Sarkar

06 October 2026 03:48 PM AEDT

Alcidion Group (ASX:ALC): FY26 Results, Healthcare Software Expansion and Contract Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Alcidion Group (ASX:ALC) reported FY26 Revenue of A$51.6 million, representing a 27% increase from the previous financial year.
Annual Recurring Revenue reached A$38.3 million at 30 June 2026, while underlying EBITDA increased to A$6.8 million.
The company expanded its healthcare software operations through the Acquisition of the Kyra flow products and a seven-year electronic patient record contract with University Hospitals Sussex.
At the time of writing this article, Alcidion Group (ASX) was trading at AUD 0.105, up 5.00% during today’s trading session.

At the time of writing this article, Alcidion Group (ASX:ALC) was trading at AUD 0.105, up 5.00% during today’s trading session. Alcidion is a healthcare technology company providing software designed to support clinical workflows, patient flow, virtual care and electronic patient records. FY26 included higher revenue, increased recurring revenue and further expansion of its healthcare customer base across Australia and the United Kingdom. The company also completed an acquisition that added patient-flow products and customers to its Australian operations.

Company Business

Alcidion develops healthcare software centred on its Miya Precision platform. The platform is designed to bring information from multiple healthcare systems into clinical and operational workflows, enabling healthcare organisations to manage patient information, clinical tasks, patient flow and decision-support processes.

Its solutions include patient flow, virtual care, operations centre capabilities, integrated care records, clinical workflow tools and modular electronic patient record functionality. Alcidion operates principally across Australia, New Zealand and the United Kingdom and supplies technology to hospitals and healthcare organisations.

The company’s Business model incorporates recurring product revenue from software licences, hosting and support arrangements, alongside implementation and technical services revenue associated with deployment of its products. Miya Precision is the principal platform underpinning Alcidion’s broader healthcare technology offering.

Recent Development

During 2026, Alcidion expanded its Australian patient-flow operations through the acquisition of the business and Assets associated with Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ. The products are used to manage inpatient and outpatient workflows, including bed management, patient journeys, referrals, triage, check-ins and healthcare data reporting.

The acquisition expanded Alcidion’s customer footprint across Australia, including healthcare providers in Queensland, Victoria, Western Australia and Tasmania. The company stated that the transaction added more than 30 healthcare provider customers, with only two already using Alcidion products.

Another development was the signing of a seven-year electronic patient record contract with University Hospitals Sussex NHS Foundation Trust in the United Kingdom. Under the arrangement, Alcidion will deploy Miya Precision, including electronic observations and assessments, alongside virtual care functionality. The system is intended to support almost 20,000 staff across seven hospitals and community services, with phased introduction scheduled from spring 2027.

Alcidion also continued expanding its remote patient monitoring activities in Australia. During March 2026, the company announced a contract with Gold Coast Health to deploy Miya Precision for remote patient monitoring and support the delivery of virtual care into patients’ homes.

Financial Performance and Sector Context

For FY26, Alcidion reported revenue of A$51.6 million, up 27% from FY25. Annual Recurring Revenue was A$38.3 million at 30 June 2026, representing an increase of 34%, while underlying EBITDA reached A$6.8 million, up 34% from the previous year. The company also generated positive Operating Cash Flow of A$6.8 million.

Gross profit for FY26 was A$41.5 million, with a gross Margin of 80.3%. Alcidion ended the financial year with A$20.6 million in cash and no debt. Contracted and renewal revenue for FY27 stood at A$44.9 million as at 30 June 2026.

These full-year results followed H1 FY26 revenue of A$25.5 million, up 44% year on year. At the half-year point, recurring product revenue was A$19.3 million and Annual Recurring Revenue stood at A$31.1 million. Underlying EBITDA for the period was A$4.2 million, while net profit was A$1.3 million.

Alcidion operates within the digital healthcare sector, where hospitals are increasingly implementing electronic patient records, patient-flow systems and virtual-care tools. Contract timing, deployment schedules and procurement processes remain important factors because healthcare technology projects can involve extended implementation periods.

Risks to Consider

Alcidion is exposed to project execution risks associated with deploying healthcare technology across complex hospital environments. Delays in implementation or procurement processes may affect the timing of revenue recognition.

The company also faces competition in electronic patient records, patient-flow software and other healthcare technology markets. Customer concentration, contract renewals, integration requirements and Cybersecurity remain relevant operational considerations.

The Kyra acquisition introduces additional integration requirements as Alcidion incorporates the acquired products and customer relationships into its broader business.

What to Watch Next

Investors may monitor implementation of the University Hospitals Sussex electronic patient record program ahead of its planned phased deployment from 2027. Progress in integrating the Kyra patient-flow products and expanding Alcidion solutions across the acquired customer base will also be relevant.

Other areas to monitor include movements in Annual Recurring Revenue, conversion of FY27 contracted revenue, operating cash flow and further healthcare software contract announcements across Australia, New Zealand and the United Kingdom.

Key Insights

Alcidion completed FY26 with higher revenue, underlying EBITDA and Annual Recurring Revenue compared with the previous financial year. Its operational developments included the Kyra flow products acquisition, continued deployment of Miya Precision and the signing of a seven-year electronic patient record contract with University Hospitals Sussex.

The company enters FY27 with contracted and renewal revenue of A$44.9 million. Future developments will centre on contract implementation, recurring revenue progression, acquired-business integration and continued deployment of healthcare technology across its core markets.

FAQs

Q:What does Alcidion Group do?

A:Alcidion develops healthcare technology used for electronic patient records, clinical workflows, patient flow, virtual care and healthcare data management.

Q:What revenue did Alcidion report for FY26?

A:Alcidion reported FY26 revenue of A$51.6 million.

Q:What was Alcidion’s underlying EBITDA in FY26?

A:The company reported FY26 underlying EBITDA of A$6.8 million.

Q:What did Alcidion acquire during 2026?

A:Alcidion acquired the business and assets associated with Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ.

Q:What are the main developments to monitor for Alcidion?

A:Key areas include implementation of major healthcare contracts, integration of the Kyra products, Annual Recurring Revenue, operating cash flow and future contract activity.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.